Tools from both firms will be offered to biopharma, diagnostic, and academic clients for biomarker discovery and validation.

Expression Pathology and Oridis Biomed joined forces to offer tissue microproteomic capabilities for protein biomarker discovery and validation. “This alliance will provide a powerful new option for drug and diagnostic developers to identify and measure protein biomarkers that relate to specific disease progression, drug response, and toxicity,” remarks Casey Eitner, CEO, Expression Pathology.

The relationship combines the Expression Pathology’s Liquid Tissue® and Director™ technologies, which enable mass spectrometry-based discovery and measurement of protein biomarkers in archival tissue, with Oridis’ Tissomics™ research platform for high-throughput analysis of healthy and diseased patient tissue and its access to formalin-fixed tissue samples associated with longitudinal clinical and pathology information.

“This partnership provides a unique opportunity to mine tissue archives with detailed clinical outcomes and pathology data by mass spectrometry and state-of-the-art pathology techniques,” states Peter Hecht, Ph.D., CEO Oridis.

Under the terms of the agreement, both companies will offer collaborative research capabilities and services to biopharmaceutical, diagnostic, and academic clients. Each firm will also serve as a business development agent to its partner’s technologies in its domestic geographical markets.

Previous articleACT Bolsters IP Portfolio with hESC Technology from Wisconsin Alumni Research Foundation
Next articleBristol-Myers Squibb Is Newest Member of Oslo Cancer Cluster